Trajectories of Prescription Drug Misuse Among US Adults From Ages 18 to 50 Years.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
04 01 2022
Historique:
entrez: 4 1 2022
pubmed: 5 1 2022
medline: 26 2 2022
Statut: epublish

Résumé

US adults born from 1965 to 1996 had high exposure to controlled medications, yet little is known about how this exposure has affected them over time. Prescription drug misuse (PDM) has increased among adults in the past 2 decades, with related increases in emergency department visits, overdoses, and deaths. To identify 32-year PDM trajectories involving opioids, stimulants, and sedatives or tranquilizers and to examine associations between these PDM trajectories and substance use disorder (SUD) symptoms in adulthood as well as between baseline characteristics and PDM trajectories. This cohort study included 11 cohorts of adolescents who were followed up longitudinally from age 18 years (study start, 1976-1986) to age 50 years (2008-2018) in the Monitoring the Future (MTF) study, which included a national multistage random sample of US 12th grade students. Baseline surveys (modal age 18) were self-administered in classrooms. Ten follow-ups were conducted by mail. Data analysis was conducted from December 2020 to October 2021. Sociodemographic variables were measured at baseline. PDM and SUD symptoms were measured at baseline and every follow-up. Latent profile analysis (LPA) was used to create PDM trajectory profiles. Associations between these PDM trajectories, SUD symptoms, and baseline sociodemographic characteristics were examined. The sample of 26 575 individuals was 50.8% (95% CI, 50.2%-51.4%) female and 79.3% (95% CI, 78.8%-79.8%) White. The baseline response rate ranged from 77% to 84%, and the 32-year retention rate was 53%. In adjusting for attrition, 45.7% (95% CI, 44.9%-46.4%) of the respondents reported past-year PDM at least once during the 32-year reporting period. Among those who reported PDM, the prevalence of poly-PDM was 40.3% (95% CI, 39.3%-41.3%). Based on LPA, the number of class-specific PDM trajectories ranged from 4 (prescription opioids) to 6 (prescription stimulants). For the class-combined analyses, we identified 8 PDM trajectories consisting of early peak trajectories (eg, age 18 years), later peak trajectories (eg, age 40 years), and a high-risk trajectory (eg, high frequency PDM at multiple ages). All PDM trajectories were associated with increased odds of developing SUD symptoms in middle adulthood, especially the later peak and high-risk trajectories compared with early peak trajectories (eg, peak at age 40 years: adjusted odds ratio [aOR], 5.17; 95% CI, 3.97-6.73; high-risk: aOR, 12.41; 95% CI, 8.47-18.24). Baseline characteristics associated with a high-risk trajectory were binge drinking (aOR, 1.69; 95% CI, 1.13-2.54), cigarette smoking (aOR, 2.30; 95% CI, 1.60-3.29), and marijuana use (aOR, 3.78; 95% CI, 2.38-6.01). More recent cohorts (eg, 1985-1986) had a higher risk of belonging to later peak PDM trajectories (ages 40 and 45 years) than the 1976-1978 cohort (age 40 years peak: aOR, 2.49; 95% CI, 1.69-3.68). In this cohort study, adults with later peak PDM trajectories were at increased risk of SUD symptoms in middle adulthood. These findings suggest the need to screen for PDM and SUD from adolescence through middle adulthood.

Identifiants

pubmed: 34982159
pii: 2787580
doi: 10.1001/jamanetworkopen.2021.41995
pmc: PMC8728613
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2141995

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA001411
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA043691
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA031160
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA016575
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA042146
Pays : United States
Organisme : NIDA NIH HHS
ID : UH3 DA050252
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA036541
Pays : United States

Références

Addict Behav. 2011 Jan-Feb;36(1-2):79-86
pubmed: 20864261
Drug Alcohol Depend. 1996 Jun;41(2):101-12
pubmed: 8809498
Lancet Psychiatry. 2019 Oct;6(10):840-850
pubmed: 31521577
Biometrics. 1988 Dec;44(4):1049-60
pubmed: 3233245
J Stud Alcohol Drugs. 2011 Jan;72(1):106-16
pubmed: 21138717
J Stud Alcohol Drugs. 2015 Jan;76(1):5-20
pubmed: 25486389
J Adolesc Health. 2012 Jul;51(1):6-17
pubmed: 22727071
Addiction. 2008 May;103 Suppl 1:84-99
pubmed: 18426542
J Consult Clin Psychol. 1998 Jun;66(3):474-83
pubmed: 9642885
J Stud Alcohol. 2001 Mar;62(2):150-7
pubmed: 11327181
JAMA. 2020 Jun 9;323(22):2301-2309
pubmed: 32515821
Psychiatr Serv. 2019 Feb 1;70(2):97-106
pubmed: 30554562
JAMA Psychiatry. 2015 Aug;72(8):757-66
pubmed: 26039070
MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):349-358
pubmed: 29596405
Subst Abuse. 2016 May 25;9(Suppl 1):41-57
pubmed: 27257384
Addict Behav. 2016 Sep;60:219-22
pubmed: 27163188
Addiction. 2014 Jan;109(1):102-10
pubmed: 24025114
Pain Med. 2020 Oct 1;21(10):2237-2243
pubmed: 31816076
Am J Epidemiol. 2003 Feb 15;157(4):364-75
pubmed: 12578807
Am J Psychiatry. 2016 Jun 1;173(6):588-99
pubmed: 26940807
Addict Behav. 2019 Mar;90:285-293
pubmed: 30472537

Auteurs

Sean Esteban McCabe (SE)

Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan, Ann Arbor.
Institute for Social Research, University of Michigan, Ann Arbor.
Institute for Research on Women and Gender, University of Michigan, Ann Arbor.
Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.

John E Schulenberg (JE)

Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan, Ann Arbor.
Institute for Social Research, Department of Psychology, University of Michigan, Ann Arbor.

Ty S Schepis (TS)

Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan, Ann Arbor.
Department of Psychology, Texas State University, San Marcos.

Rebecca J Evans-Polce (RJ)

Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan, Ann Arbor.

Timothy E Wilens (TE)

Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan, Ann Arbor.
Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston.

Vita V McCabe (VV)

Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan, Ann Arbor.
Department of Surgery, University of Michigan, Ann Arbor.
Department of Psychiatry, University of Michigan, Ann Arbor.

Philip T Veliz (PT)

Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan, Ann Arbor.
Institute for Social Research, University of Michigan, Ann Arbor.
Institute for Research on Women and Gender, University of Michigan, Ann Arbor.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH